title: Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?
abstract: Cancer is one of the most wide-spread diseases of modern times, with an estimated increase in the number of patients diagnosed worldwide, from 11.3 million in 2007 to 15.5 million in 2030 (www.who.int). In many cases, due to the delay in diagnosis and high increase of relapse, survival rates are low. Current therapies, including surgery, radiation and chemotherapy, have made significant progress, but they have many limitations and are far from ideal. Although immunotherapy has recently offered great promise as a new approach in cancer treatment, it is still very much in its infancy and more information on this approach is required before it can be widely applied. For these reasons effective, safe and patient-acceptable cancer therapy is still largely an unmet clinical need. Recent knowledge of the genetic basis of the disease opens up the potential for cancer gene therapeutics based on siRNA. However, the future of such gene-based therapeutics is dependent on achieving successful delivery. Extensive research is ongoing regarding the design and assessment of non-viral delivery technologies for siRNA to treat a wide range of cancers. Preliminary results on the first human Phase I trial for solid tumours, using a targeted non-viral vector, illustrate the enormous therapeutic benefits once the issue of delivery is resolved. In this review the genes regulating cancer will be discussed and potential therapeutic targets will be identified. The physiological and biochemical changes caused by tumours, and the potential to exploit this knowledge to produce bio-responsive 'smart' delivery systems, will be evaluated. This review will also provide a critical and comprehensive overview of the different non-viral formulation strategies under investigation for siRNA delivery, with particular emphasis on those designed to exploit the physiological environment of the disease site. In addition, a section of the review will be dedicated to pre-clinical animal models used to evaluate the stability, safety and efficacy of the delivery systems.
authors: Pharmacodelivery Group, School of Pharmacy, University College Cork, Cork, Ireland.
authors: Jianfeng
authors: J
authors: Guo
authors: Ludovic
authors: L
authors: Bourre
authors: Declan M
authors: DM
authors: Soden
authors: Gerald C
authors: GC
authors: O'Sullivan
authors: Caitriona
authors: C
authors: O'Driscoll
mesh_terms: D000818:Animals; D004354:Drug Screening Assays, Antitumor; D018014:Gene Transfer Techniques; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D009369:Neoplasms / Q000628:therapy*; D034741:RNA, Small Interfering / Q000008:administration & dosage* / Q000627:therapeutic use*; D014780:Viruses / Q000235:genetics
chemical_list: D034741:RNA, Small Interfering